Our Services
Medical Information
Helpful Resources
Published on: 4/24/2026
Wegovy (semaglutide) can trigger mood changes, including depression, through biological, nutritional, and psychological pathways. Deciding whether to switch medications requires weighing depressive symptom severity against weight loss benefits and exploring alternatives with your healthcare provider.
Key considerations include your risk profile, alternative GLP-1 medications, and management strategies before making any changes.
If you're experiencing mood changes or depressive symptoms while taking Wegovy, don't wait to get clarity. A free, instant, online symptom check can help you evaluate your symptoms in minutes, understand potential causes, and identify the right next steps—whether that's talking to your doctor about dose adjustments, switching medications, or seeking mental health support. Taking a few minutes now could save you weeks of uncertainty.
Reviewed for medical accuracy: 07/10/2026
Wegovy (semaglutide) has become a popular prescription for weight management, but some patients report mood changes, including depression. If you're wondering "why does Wegovy cause depression?" you're not alone. This article explores the science behind these reports, outlines possible mechanisms, and offers guidance on whether you should switch medications.
Wegovy is a once-weekly injectable medication that mimics a hormone called GLP-1 (glucagon-like peptide-1). It controls appetite and helps you feel full, leading to weight loss. Approved by the FDA in 2021 for chronic weight management, it's generally safe, but like all drugs, it can have side effects.
Clinical trials and real-world use have documented:
Most mood-related side effects are mild, but some people experience significant sadness or even suicidal thoughts.
There isn't a single proven answer yet, but researchers propose several hypotheses:
Direct Central Nervous System (CNS) Effects
Nutritional Deficiencies
Rapid Weight Loss Stress
Indirect Hormonal Fluctuations
Individual Vulnerability
If you're taking Wegovy, monitor yourself (or loved ones) for:
If you notice any of these, it's important to take action.
Deciding whether to stop or switch Wegovy is a personal choice that should involve your healthcare provider. Consider:
Severity of Depression
• Mild, short-lived mood changes may improve as your body adjusts.
• Moderate to severe depression or suicidal thoughts require prompt medical attention.
Alternative Treatments
• Other GLP-1 receptor agonists (e.g., Ozempic) carry similar risks.
• Non-GLP-1 options include bupropion/naltrexone (Contrave) or orlistat (Xenical).
• Lifestyle interventions: diet, exercise, cognitive behavioral therapy (CBT).
Risk–Benefit Analysis
• Compare the mental health impact against weight-loss benefits (reduced diabetes risk, improved heart health).
• Discuss your goals, concerns, and any previous history of mood disorders with your doctor.
Monitoring Plan
• Schedule regular check-ins to assess mood and nutritional status.
• Consider blood tests for B12, iron, thyroid function.
Staying proactive about your mental health is key. If you're experiencing concerning symptoms and want to better understand what might be causing them, you can check your symptoms with a free AI-powered assessment to help organize your concerns before discussing them with your healthcare provider.
If you experience any of the following, contact a healthcare professional or call emergency services right away:
Wegovy can be an effective tool for weight loss, but it may affect mood in some individuals. Understanding "why does Wegovy cause depression" involves a mix of biological, nutritional, and psychological factors. If you're struggling, discuss your symptoms with your doctor. You may need to adjust your dosage, switch medications, or add supportive therapies.
Always take mental health changes seriously. Speak to a doctor about anything that could be life-threatening or serious. Your well-being—both physical and mental—is worth prioritizing.
(References)
* Liu J, Li J, Yu X. Adverse Events of Semaglutide in Clinical Trials: A Systematic Review and Meta-Analysis. Front Pharmacol. 2023 Feb 15;14:1107530. doi: 10.3389/fphar.2023.1107530. PMID: 36873995; PMCID: PMC9975765.
* Lee YH, Kim SK, Lee DH. The Effect of Glucagon-like Peptide-1 Receptor Agonists on Depressive Symptoms: A Systematic Review and Meta-Analysis. J Clin Endocrinol Metab. 2020 Jan 1;105(1):e147-e158. doi: 10.1210/clinem/dgz137. PMID: 31737633.
* Mansoor N, Naqvi SAA, Batool S, Iqbal A, Khan MSA, Rizvi SAA. Impact of Glucagon-Like Peptide-1 Receptor Agonists on Mood and Anxiety in Patients with Type 2 Diabetes Mellitus and Obesity: A Systematic Review. Cureus. 2022 Jul 3;14(7):e26526. doi: 10.7759/cureus.26526. PMID: 35928135; PMCID: PMC9349885.
* Fralick M, Kim D, Kesselheim AS, Avorn J. Suicidal Ideation and Behavior With GLP-1 Receptor Agonists for Weight Loss. JAMA. 2024 Jan 9;331(2):167-168. doi: 10.1001/jama.2023.25057. PMID: 38190288.
* Wróblewski Ł, Węgrzynowska M, Szymańska M, Sura E. Weight Loss and Mental Health in Obesity: A Bidirectional Relationship. Nutrients. 2023 May 10;15(10):2250. doi: 10.3390/nu15102250. PMID: 37241853; PMCID: PMC10221319.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.